492 results found

A casual observer of China’s competition law regime could be excused for assuming that antitrust-related enforcement has been scaled back in the lead up to the second anniversary of the commencement of the Anti-Monopoly Law (AML), given the absence of significant new merger control decisions and the continued paucity of AML conduct rule cases.

On 10 December 2024, the State Administration for Market Regulation ("SAMR") released the Guidelines for Review of Horizontal Concentration of Undertakings ("Guidelines").

This client briefing discusses the recent trend of enforcement actions taken by the Chinese merger control regulator, the Ministry of Commerce ("MOFCOM") against ‘failures to notify' under Art. 21...

Five years ago, MNCs could translate superior technology, products, and management models into easy profits in the world's second-largest economy. Today, the competitive landscape has shifted.

Last month, the China Securities Regulatory Commission (CSRC) issued a notice listing the documents that must be submitted when CSRC approval is required in connection with an offshore listing or going-public transaction involving a Chinese operating company.

Following continuous decline of China's economy, the ratio of non-performing loans ("NPL") in commercial banks continues to grow.

The SAMR maintained a consistently rigorous and prudent attitude towards merger control review in 2019.

Meta's acquisition of Manus has sparked widespread attention in China, raising critical questions about foreign investment security review compliance. When a domestic AI company transfers core business assets overseas before selling to a foreign buyer, does this constitute a reviewable transaction under Chinese law? This analysis examines the regulatory framework and compliance implications for cross-border technology deals.

Overview: In June 2023, significant developments in the TMT legal sector included new regulations and guidelines issued by various authorities.

While many fintech investors were cautiously optimistic heading into 2025, the combination of headwinds from ongoing geopolitical tensions and rapidly evolving concerns over tariffs...

A number of acquisition loan arrangements have already been inked since the China Bank Regulatory Commission ("CBRC") issued new guidelines (the "Guidelines") on December 6, 2008 allowing commercial banks to provide loans to domestic enterprises conducting acquisitions within China and abroad.

In the previous article, Combating Increased Internal Fraud: Lessons from Recent Cases and Proactive Risk Mitigation Strategies, we examined the common themes and patterns in recent internal fraud cases across...

A Paris roundtable examined China's transformation into a biotechnology powerhouse and the strategic opportunities this creates for European life sciences companies and investors. Industry leaders discussed how to structure cross-border partnerships that leverage Chinese innovation and development speed while navigating intellectual property protection, regulatory frameworks, and evolving geopolitical considerations.

On 3 February 2011 a new circular entitled "Circular of the General Office of the State Council on the Establishment of a Security Review System Regarding Mergers and Acquisition of Domestic Enterprises by Foreign Investors" was published by China’s State Council.

On March 4, 2011, the Ministry of Commerce of People’s Republic of China ("MOFCOM") issued initial procedural rules to implement the new mechanism, announced on February 3, 2011, by which certain foreign direct investment transactions will be reviewed on national security grounds.

China has emerged as a global pharmaceutical innovation powerhouse, leveraging its scientific expertise, AI capabilities, and streamlined regulatory environment to accelerate drug development.

People are growing increasingly conscientious about their health, and the pharmaceutical industry has become an important part of the national economy.

2020年已接近尾声，但从2019年开始大热的SPAC热度丝毫未减。